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Abstract
Introduction
Current achievement in immunology promoted the immune 
cells as powerful therapeutic antigens, targeting tumor 
antigens with T cells expressing chimeric antigen receptors 
(CARs), especially in lymphoid malignancies patients.(1-3) 
However, a potentially fatal cytokine release syndrome was 
reported in a significant number of subjects and requiring 
intensive care unit (ICU) admission. Then, despites its 
promising results in treating cancer, this give a big challenge 
to enact it available for a larger number of patients.(4)
 Increasingly considered as promising immuno-
therapeutic agents for cancer, Natural Killer (NK) cells 
have advantages because they are potentially broadly 
applicable and do not cause graft-versus-host disease such 
as other T cells counterparts.(5) NK cells have an important 
role in cancer immunosurveillance as a part of innate 
immune system.(6,7) They don’t need peptide antigen to 
be presented in major histocompatibility complex (MHC) 
molecules foregoing, because their activity were controlled 
by distinct germline-encoded cell surface receptors so the 
healthy and diseased tissue can be distinguished.(8,9) The 
problem is, in cancer patients, the immunosuppressive 
tumor microenvironment was generally impaired, so the NK 
cell responses were also impaired. That’s why current NK 
cell therapies were commonly performed with allogeneic 
adoptive transfer from a suitable donor’s NK cell which had 
expanded ex vivo.(10-12)
 Primary NK cells usually have a limited of life span 
and expansion potential, but the NK cell line NK-92, with 
help of interleukin (IL)-2 can be continuously expanded in 
a good manufacturing practices (GMP)-compliant process.
(13) Early phase clinical trials for safety and clinical 
activity of NK-92 cells for allogeneic therapy in patients 
with advanced malignancies showed a good result.(13-
15) Preclinical studies using both NK-92 primary human 
NK cells and investigating the generating of cluster of 
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R E V I E W  A R T I C L E
BACKGROUND: Current understanding in molecular character of natural killer (NK) cell, its function and mechanisms, send people the ideas 
to develop a NK-cell-based immunotherapeutic strategies 
against human cancer.
CONteNt: Before being regards as a cell-based cellular 
therapy, NK cell have to be clinical proven. Early studies 
with NK cells infusions for acute myeloid leukemia and 
lung cancer showed a promising result. NK cells need 
simplified methods for enriching and expanding, in addition 
to its transfection with chimeric antigen receptors (CARs). 
NK-92 arise as an assuring effector cells to augment 
monoclonal and bispecific antibody therapy. Thus, NK cells 
show a potential opportunity for cell engineering, outstep 
the era of T cells.
SUmmARy:  It is believed that NK cells bring a bright 
hope for future cancer immunotherapies, either alone or in 
combination as a harmonious therapy.
KeywORDS: NK cells, NK-92 cells, immunotherapy, 
CAR
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differentiation (CD)19-specific chimeric antigen receptors 
(+) NK cells.(16-18) By that, compared than limited original 
T cells (17-21),  CAR-engineered cells can be isolated 
and expanded from bulk of non-transduced cells (19-22). 
Thus, donor-derived allogeneic cells immunotherapy were 
being preferred for adoptive cancer because the cells do not 
recognize tumor cells as 'self', and can bypassing inhibitory 
signals.(10,11) This advantage may be extended to NK-92 
cells that do not express most of the inhibitory killer cell 
immunoglobulin-like receptors (KIRs) and phenotypically 
resemble activated NK cells.(5,23) This approach could 
be potentially utilized for solid tumor or hemotological 
malignancies cases, where CAR-engineered NK-92 cells 
will target antigens expressed by cancer cells.(17,19,20,24-
28)
Human Natural Killers Cells
T cell receptor (TCR) and antibody/B cell receptor (BCR) 
produced by the site-specific somatic recombination of 
these cells.(29)
 NK cells first illustrated as large granular 
lymphocytes, and has natural cytotoxicity to counter tumor 
cells. Later on people recognized NK cells as a separate 
lymphocyte lineage with cytokine-producing effector 
function besides its cytotoxicity (Figure 1).(29,30) NK 
cell activity regulation including the NK cell detection 
system involving the activation of a variety of cell surface 
and the inhibitory receptors. There will be an equilibrium 
between the integration of antagonistic pathways upon 
interaction with neighboring cells to decide the activation 
of NK cells to kill target cells.(31) When activated, NK cell 
receptors will detect a distress on cells ligands, for example 
the stress-induced self ligands which recognized by some 
slert molecules like the NK group 2D (NKG2D).(32) 
There are also alert molecules such as nonself ligands (the 
cytomegalovirus-encoded m157 recognized by Ly49H in 
the mouse) and Toll-like receptor (TLR) ligands. Naturally, 
NK cells express several TLRs which can induces interferon 
(IFN)-γ production and enhances cytotoxicity in vitro.(33)
 Like any other lymphocytes, during their development 
NK cell acquire tolerance to self. This does not always occur 
but NK cell have the potential to attack normal self cells.(34) 
NK cells utilize the absence mensuration of consecutively 
The immune system is divided into two parts, called the 
acquired immune system and the innate immune system. 
Innate immunity was typically characterized with a broadly 
distributed variety of myeloid and lymphoid cells and the 
rapid responses through a defined repository of germline-
encoded receptors. In the contrary, adaptive immunity in 
mammals was defined by two lymphocytes, T and B cells. 
Figure 1. the biological functions of NK 
cells. NK cells can recognize a variety 
of stressed cells in the absence or in the 
presence of antibodies (blue arrows). NK 
cell activation triggered by this recognition 
can lead to the lysis of the target cell and 
to the production of various cytokines 
and chemokines depending on the nature 
of the stimulation.(29) (Adapted with 
permission from American Association for 
the Advancement of Science).
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Figure 2. NK cell receptors. NK cells 
express many cell surface receptors that can 
be grouped into activating (green), inhibitory 
(red), adhesion (blue), cytokine (black) and 
chemotactic receptors (purple). In addition to 
MHC class I–specific receptors, other NK cell 
inhibitory receptors specific for non-MHC 
ligands also regulate NK cell reactivity.(29) 
(Adapted with permission from American 
Association for the Advancement of Science).
expression of self’s molecule on susceptible target cells. In 
several in vitro and in vivo models, MHC class I-specific 
receptors expressed by NK cells lose its inhibitory signals 
when encountering hematopoietic cells with MHC class 
I-deficient. This usually happened when cells were flustered 
due to viral infection or cellular transformation.(35,36) The 
fallout effects, this missing self on hematopoietic cells will 
be recognized by NK cells.(37) This recognition happened 
due to the NK cells inhibitor receptors specific to MHC class 
I, including KIRs in humans, lectin-like Ly49 molecules 
in mice, and CD94/NKG2A heterodimers in both species.
(38,39) The MHC class I-specific inhibitory receptors 
include the KIRs in humans, the lectin-like Ly49 dimers in 
the mouse and the lectin-like CD94-NKG2A heterodimers 
in both species (Figure 2).(35,36)
 Intracytoplasmic Immunoreceptor tyrosine-based 
inhibitions motifs (ITIMs)  mediates the signal to activate 
the large family of inhibitory receptors including MHC 
class I receptors.(31) Therefore NK cell can distinguish 
and spare healthy cells which express self MHC class I 
molecules accompanied by low amounts of stress-induced 
self molecules, while dejected cells with down-regulated 
MHC class I molecules and/or high level of stress-induced 
self molecules, such as NKG2D ligands.(40) Figure 3 shows 
a diagram describing balance of inhibitory and stimulatory 
signals received by a natural killer.
 So we’ve figure out that NK cells can influence the 
host’s immune response via cytokine and chemokine and 
kill certain infected or transformed cells through perforin/
granzyme or death receptors-related pathways such as 
Fas, and tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL).(40-46) The prototypic cytokine 
secreted by NK cells is IFN-g. It has the ability to shape 
the Th1 immune response (44), activate  antigen-presenting 
cell (APC) for MHC class I further upregulate expression 
(47), activate macrophages to kill the restricted intracellular 
pathogens (48), and anti-proliferating effect on viral and 
malignant-transformed cells (49).
 NK cells in human is phenotypically and functionally 
heterogeneous. NK cells which were rich with CD56+ 
surface molecules were primarily cytokine-secreting cells, 
found about 10% NK cells found in blood, and almost 
100% in secondary lymphoid tissues. They can be activated 
within minutes to secrete cytokines and chemokines, but 
these CD3−CD56+NKp46+ cells barely can spontaneously 
kill tumor cell targets.(50) Otherwise, Circulating NK 
195
The Indonesian Biomedical Journal, Vol.10, No.3, December 2018, p.192-202 Print ISSN: 2085-3297, Online ISSN: 2355-9179
Figure 3. the balance of inhibitory and 
stimulatory signals received by a natural killer 
cell determines the outcome of interactions with 
target cells.(37) (Adapted with permission from 
Springer International Publishing AG).
cells with low surface density (called dim expression of 
CD56 and NKp46) does not express cytokines as agile as 
the other type but some, but not all, have the ability to lyse 
susceptible tumor cell targets sprightly.(51) however both 
types have relatively distinct and balanced important roles 
during human immune response.(52-55) despite its cytokine 
secretion or cytotoxicity, NK cell was tightly regulated by 
the balancing of its activation and inhibition signals which 
are integrated in a complex network expressed from its cell 
surface receptors, and we have the ideas that the immune 
system can be engineered to cure some forms of cancer.(56)
Targeting NK Cells in Cancer Immunotherapy
Formerly, people pit most attention at T lymphocytes for 
immunotherapy strategies, but new discoveries showed the 
potential of NK cells as better effector cells for treating 
cancer. The cytotoxicity effects, together with cytokine 
secretion, especially IFN and granulocyte-macrophage 
colony-stimulating factor, assign them at the crossroads of 
innate and adaptive immunity. Through antibody-mediated 
cellular cytotoxicity, the activity of monoclonal antibody 
can be enhancing and can be transfected with chimeric 
antigen receptors.(57) As their name suggests, NK cells 
spontaneously kill cells deemed to be dangerous to the 
host (cancer, foreign or virus-infected cells) and thus are 
presumed to be key effectors in cancer immunosurveillance, 
transplantation rejection and early viral immunity.(33) 
NK cells are usually defined as CD3−CD56+ cells in 
humans and CD3−NK1.1+ or CD3−NKp46+ cells in mice. 
CD56loCD16+ NK cells with high cytotoxic potential mostly 
found in human blood, whereas the immunomodulatory 
CD56hiCD16− subset found more in lymph nodes. NK 
cells serve as 5-15% of human circulating lymphocytes, 
classified as different population based in their maturation 
and specific function.(58,59)
 NK cells have developed several mechanisms for 
distinguishing healthy cells from target cells. These 
mechanisms form the basis of NK cell activation and cannot 
be  considered  in  isolation  but  instead  must  be considered 
as complex integration of signals from an array of receptors. 
By binding with self MHC class I, NK cells tolerate to self-
tissue and allows the licensing of NK cells by the engagement 
with MHC class I. Cells with downregulated expression of 
MHC class I such as in malignant cells, will put the NK 
cells inhibitory signals off and permit their function.(37,38)
 Granzyme B and perforin are the core molecules 
required for NK cell–mediated tumor killing (60), although 
death-receptor pathways (involving FasL and TRAIL) 
are sometimes used. Furthermore, NK cells secrete pro-
inflammatory cytokines and chemokines (such as IFN-γ, 
TNF, IL-6, granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and chemokine C-C motif ligand 5 (CCL5)) 
that might exert direct anti-tumor activity in addition  to 
promoting  innate  and  adaptive responses.  Thus,  NK cells 
are not only killers but also immunoregulatory cells that can 
positively or negatively influence anti-cancer responses by 
modulating the responses of dendritic cells (DCs) and T cells.
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(61) Another mechanism linked to the immunosurveillance 
of cancer by NK cells involves the elimination of senescent 
cells. Indeed, the cytokines and chemokines associated with 
the senescence-associated secretory phenotype mobilize 
effective NK cell responses (62).
 NK cells can be derived from various sources and can 
be obtained from the patient (autologous setting) or from a 
healthy donor (allogeneic setting). Few NK cells circulate in 
human blood, and naive NK cells exhibit limited cytotoxic 
activity. For these reasons, several protocols have been 
designed to expand large numbers of NK cells with full 
anti-tumor functions. These methods have been discussed 
before.(63,64) Previous trials showed that NK cells 
autologous infusion are clinically ineffective, even with 
concomitant administration of cytokines such as IL-2.(65-
67) Thus the focus shifted to allogeneic administration from 
donor, usually obtained by apheresis to obtain mononuclear 
cells, majority peripheral blood mononuclear cells (PBMC). 
There are still challenges including to consistently obtain 
sufficient numbers of cells for patient treatment, as we 
know NK cells only present approximately 10% of all 
lymphocytes in the blood, and the other issue is to remove 
T cells which can induce Graft versus host disease (GvHD) 
in the recipient, commonly using negative CD3 depletion 
using  immunomagnetic antibody tagging with subsequent 
absorption of the cells over a magnetic column (i.e., 
the Miltenyi CliniMACS system, Bergisch-Gladbach, 
Germany).(68,69)
 Recently the interest shifted to NK cells from 
umbilical cord blood which is readily available with no risk 
or aggravation for donor. Frozen cord blood cells either 
cryopreserved or not, can serve as starting material. NK cells 
in cord blood are immature, so they must be cultured for 
several weeks with a cocktail of cytokines which contains 
a combination of IL-2, IL-15, FMS-like tyrosine kinase 3 
ligand (Flt-3L) and IL-3 on positively selected cord blood 
NK cells were placed on a feeder layer of mesenchymal 
stromal cells, until reach an acceptable NK cell numbers, 
average at a median of 60-fold.(57,70)
 However, this expansion process is costly and 
burdensome, restricted process in a GMP-standard 
laboratory, performed in gas-permeable bags, in flasks or 
in bioreactors that expand larger cell numbers on a smaller 
footprint. To reduce the cost, any manipulation must be done 
before culture expansion, so the material and time cost will 
be less. The bag system is a good choice for it does not need 
wide spaces for sterile and closed system. Some company 
offers automated technology for cell expansion including 
Milteny’s Prodigy (Miltenyi Biotec GmbH, Bergisch-
Gladbach, Germany) with their closed system in constant 
medium and cytokine feed as per program, and the G-Rex 
biorecator (Wilson Wolf Manufacturing, New Brighton, 
MN, USA) expands NK cells well and simplified medium 
change as the cells collect at the bottom of the flask.(71) 
 Furthermore, with the help of cytokines and certain 
growth factors, adoptively transferred NK cells can be 
expanded and activated in vivo in conditioned patients, or 
may also combined with other treatment modalities to reach 
a synergistic antitumor activities.(72)
Recalling the cytotoxic features of NK cells as part of 
innate immunity system, they don’t need prior sensitization 
to kill any virally infected cells and tumor cells. Adequate 
number of functional NK cells that are able to proliferate in 
vivo were needed for an effective therapy but are not over-
stimulated by cytokines.(73,74) Some group study attempt 
to optimizing methods for NK cells ex vivo isolation, 
activation and expansion from peripheral blood, mainly 
for prevention and/or treatment of relapsed disease.(75,76) 
Another study using IL-2 and an artificial antigen presenting 
cell to expand umbilical cord blood NK cells ex vivo.(78) 
Particularly, there are two ongoing clinical trials testing the 
feasibility (NCT01619761 and NCT01729091). Apheresis 
become the most preferred method for collecting PBMNCs 
due to its ability to collect cells aseptically into a closed 
system and minimizing the contamination.(79)
 Previous experiences demonstrated that concomitant 
administration of cytokines such as IL-2, for NK cells 
autologous infusion are clinically ineffective (65), then 
the focus shifted to allogeneic therapy. In this case, graft-
versus-host disease in the recipient have to be prevented, by 
adding some manipulation steps in expansion process.(68) 
Substantial donor-dependent variability also found in terms 
of NK cell yield, so a continuously growing NK cell line is 
needed to provide predictable numbers of highly cytotoxic 
NK cells on expansion.(15,68,69,80-82).
 Domogala, et al., tried to modify the NK cells 
differentiation protocol, and compared the mobilized 
peripheral blood stem cells (mPBSC), fresh CB CD34+ cells 
and frozen umbilical cord blood CD34+ cells to generate 
a functional, readily available off-the-shelf product of 
NK cells, and found that the best source for NK cells is 
frozen umbilical cord blood CD34+ cells, suggested that 
NK-92 Cell Line, “Off-The-Shelf” 
for Adoptive NK Cells-based Cancer Immunotherapy
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the cryopreservation procedure selected the most potent 
UCB CD34+ cells, leading to a higher fold expansion (600 
versus 200) therefore generated a higher NK cell numbers, 
not regarding the phenotype, cytokine production or 
cytotoxicity of the cells.(83,84)
 NK cell proliferation ex vivo can generally be 
stimulated using a feeder cell such as monocytes which 
stimulate NK cell expansion by both humoral signals and 
direct cell-to-cell contact. That’s why some protocols suggest 
the using of PBMNCs as a source of feeder cells in the NK 
cell culture.(65,85-87) Moreover, two allogeneic feeder cell 
lines commonly used in NK cell expansion including an 
Epstein-Barr virus-transformed lymphoblastoid cell line and 
an engineered leukemic cell line that express a membrane-
bound form of IL-15 fused to the T cell receptor CD8a and 
the 41BB ligand.(88-90) Using allogeneic feeder cell lines 
requires irradiation, meanwhile autologous feeder cell lines 
do not need it.(69,88-91)
 NK-92 is a highly potent permanent NK cell line 
(NantKwest, Culver City, CA, USA), which is now readily 
available, processed from a cGMP-compliant master cell 
bank, predictable and reproducible amplification of an 
extensively characterized potent NK cell agent is at hand 
for clinical usage.(5) It is a permanent, IL-2-dependent 
NK cell line, first obtained from the peripheral blood of a 
50-year-old male patient with non-Hodgkin’s lymphoma at 
diagnosis in 1992, and can be kept in vented tissue culture 
asks.(92,93) NK-92 is characterized by the expression 
of CD56+ and CD2, CD3-, CD8-, and and the low-affinity 
immunoglobulin G (IgG) fragment crystallizable region 
(Fc) receptor (FcγRIII), CD16.(23) A CD56+/CD16-/ low 
phenotype is typical for a minor subset of NK cells in 
peripheral blood, which have immunomodulatory functions 
as cytokine producers.
 However, NK-92 is a highly cytotoxic cell 
line. It expressed high levels of cytolytic pathway 
molecules, including perforin and granzyme B. NK-92 
clone transformation may have emerged from an early 
undifferentiated NK cell progenitor.(13,23) CD16 receptor 
is an important feature of NK cells that mediates binding to 
antibodies through the Fc portion of IgG so it may have an 
additional killing mechanism of antibody-dependent cell-
mediated cytotoxicity (ADCC) in conjunction with tumor-
targeting antibodies. Different with primary cytotoxic 
NK cells, ADCC originally is not a cytotoxic mechanism 
naturally exerted by currently established NK cell lines 
(Figure 4).(5) Uniquely, other established cytotoxic NK cell 
lines, such as KHYG-1, NKL and YT, have inadequate of 
CD16 expression.(94)
 NK-92 cells can be easily manipulated genetically for 
specific tumor antigens recognition, or to develop antibody-
dependent cellular cytotoxicity. It has low risks and can 
be easily infused into patients, even in the advanced stage 
of cancer.(4) NK cell can be engineered to express many 
different CARs to prevent tumor resistance, by targeting for 
instance, CD19 or CD20 (anti-B cell malignancies), CD38 
(anti-myeloma) or human epidermal growth factor receptor 
2 (HER2; ErbB2; anti-epithelial cancers), with lower 
costs compared to autologous or allogeneic NK cells and, 
particularly, CAR-T cells  make it as a promising effective 
treatments in cancer.(5)
Figure 4. Simplified, schematic representation of 
NK-92 in a tumor target cell encounter compared 
to a primary NK-cell.(5) (Adapted with permission 
from Springer International Publishing AG).
CAR-expressing NK Cells
On August 2017, the forst CAR-T therapy approved 
in United States was Kymriah (tisagenlecleucel) from 
Novartis. Without  a  phase  3  trial  and  within  just  six 
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month the approval was achieved, due to the astonishing 
patients’ clinical responses. After three months’ treatment 
with Kymriah, ~83% of pediatric and adult patients (up to 
25 years old) 25 with relapsed or refractory B cell acute 
lymphoblastic leukemia (ALL) showed sufficient remission 
and curative therapy are adequate. In that event, soon Kite 
Pharma was acquired by Gilead Sciences, as a sign the 
industry believe that Kymriah will lead to other CARs. For 
CAR-T itself, a successfully overcome immunosuppressive 
tumor  microenvironments,  address  the  heterogeneity 
of  solid tumors and incorporate a wider range of antigens 
suitable  for  tumor  targeting,  to  treat  leukemia 
auspiciously.(95)
 NK cells may serve as a better alternative than CAR-
driven cytolysis. Allogeneic NK cells will induce the 
immune response and then be rejected after few days, while 
autologous NK cells will disappear after few days in line 
with its lifetime. Superior rather than T cells, NK cells’ 
spontaneous cytotoxicity activity can trigger the demise of 
target cells in a tumor associated antigens (TAA)-unrestricted 
manner via specific natural cytotoxicity receptors (NCRs), 
including NCR3 (also known as NKp30), NCR2 (also 
known as NKp44), NCR1 (also known as NKp46), and killer 
cell lectin-like receptor subfamily K, member 1 (KLRK1, 
best known as NKG2D). NK cells express Fc fragment of 
IgG, low affinity III, receptor (FcγRIII), that binds the Fc 
fragment of antibodies to elicit ADCC. NK cells owned the 
CAR-expressing NK cells and a TAA-specific monoclonal 
antibody, enable the combinations of two targeted therapies 
recognizing different (or the same) TAA(s). 
 The cytokines produced by NK cells are different than 
those from T cells, supporting the serial killing of NK cell, 
as the time-lapse videomicroscopy studies showed NK cells 
and NK-92 diligently move from one target to the next one, 
killing on as many as 7-10 cells.(96,97) CAR-modified NK 
cells were in advance complementing the therapeutic option 
to CAR-expressing T cells, applied to fight against CD19, 
CD20, CD244, and HER2 as well as CAR-expressing NK-
92 cells targeting a broader range of cancer antigens.
 NK-92 cells offer an excellence chance to be an open 
platform CAR-based immunotherapy.(19) It has a higher 
efficiency in transfection and technically simple, giving 
better results while enriching, and also less risk of oncogene 
activation and insertional mutagenesis by avoiding viral 
vectors.(17,19,97) Continuously expanded CAR NK-92 
can be clinical useful for treating cancer patients, especially 
when the suitable donors for CAR T cell was impossible. 
In phase I clinical trials, only a minority of cancer patients 
treated by repeated infusion of parental NK-92 cells 
developed anti-HLA antibodies, and no adverse events 
related to immune responses to these cells were observed.
(14,15) This advantage may also be seen with CAR NK-92 
cells.  NK-92 has a high and consistent cytotoxic activity 
expressing CD19-specific CARs that employ CD3 or CD28-
CD3 signaling domains attacking established and primary 
B-cell lymphoma and leukemia cells more effectively 
compare to a similar CD137-CD3 CAR.(12)
 CAR-modified NK-92 cells showed a potency of 
effectively treating any other types of cancer as CAR-
engineered NK cell lines (e.g., NK-92) glioblastoma 
for glioblastoma, GD2-CAR on NK-92 cells against 
neuroblastoma, CS1-CAR-expressing NK-92 cells to target 
multiple myeloma (MM) cells, and an adoptive transfer 
of CS1-CAR-modified NK-92 cells efficiently impeded 
the dissemination of human IM9 MM cells in vivo and 
prolonged the lifespan.(27,28) Retargeting of NK-92 cells 
to solid tumors-derived cells with a Her-2/neu-specific 
CAR resulted in efficient lysis of NK-resistant, ErbB2/
HER2-expressing target cells in vitro, and improved  tumor 
localization and anti-tumoral activity in vivo.(19,99) The 
ErbB2/HER2 specific CAR NK-92 cells has reached phase 
I clinical trials with cGMP requirements (20,100).
Therapeutic Aplication of NK Cells
Alloreactive NK cells win the interest as suitable and 
powerful effector cells for cellular therapy of cancer after 
hematopoietic stem cells, dendritic cells, mesenchymal 
stromal cells, unselected T lymphocytes, and antigen-
specific or regulatory T cells.(101) Have no risk of GvHD 
and having strong activity of cytotoxicity, NK cells 
efficiently and specifically redirected to recombine with 
CARs, which consist of a single-chain variable fragment 
(scFv; ectodomain) linked to intracellular signaling domains 
(endodomain).(101-104) The scFv binds to a defined target 
antigen on, i.e., cancer cells and triggers effector cell 
activation upon target engagement.(98,105) Compared to 
cytokine-induced killer cells, that oving more actively than 
NK cells, it killed both MHC-I-negative and -positive cancer 
cells, while NK cells destroyed MHC-I-negative cells only. 
Moreover, cytokine-induced killer (CIK) cells moved in all 
directions thus left longer tracks than did NK cells. CIK 
cells showed higher displacement and straightness scores 
than did NK cells, which indicates long-distance random 
migration of CIK cells.(106)
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 The potential NK cells currently has been translated 
into clinical-scale using cGMP using a variety of starting 
materials, technologies, and manipulations.(68) The cell 
line NK-92 as the most potent and promising therapeutic 
cell stand as master cell, thoroughly standardized and 
characterized.(82) After irradiation, it can be infused 
allogeneic to patients.(14) to ensure the product’s safety, 
quality control become an important part include sterility 
testing, viability, gram stain, mycoplasma testing (for 
long-term cultures and products utilizing animal-derived 
reagents), endotoxin testing (LAL Kinetic-QCL, Lonza, 
Walkersville, MD) and sorting the cell phenotype as 
determined by flow cytometry.(68,107) Another challenge 
for successful therapy with NK cells in mainstream clinical 
applications include to find the most efficient and optimal 
method to yield enough cells that clinically relevant, i.e., 
with highest tumor cytotoxicity level. The exciting future 
was saw as NK cells immunotherapy now marching from 
treating hematologic malignancy to solid tumor as well. 
The challenge ahead is how to optimally activate NK cells 
endogenously without the use of a cell infusion, perhaps by 
utilizing IL-15 or any promising proteins.(108)
Conclusion
NK cells as a part of immune system play a role in the 
first defense against diseases, including malignancies. NK 
cells provide an immediate natural response of cytolytic 
action. Recently, cell-based therapies increasingly favored 
and important as the promising treatment for cancer. 
An improved understanding of NK cell character and 
mechanism will promote to a clinical applications of this 
approach. Eventually, it might even discovered that both 
these cell types have their place in the multimodal approach 
that is required to eliminate cancer and control its recurrence.
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